Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Low-dose Fisetin Supplementation for Healthy Aging - a Triple-blind, Randomized, Placebo-controlled Trial
Authors not listed
Ove Andersen · 2025
Cellular senescence
Chronic inflammation
Senolytics
C. elegans
Human
Mouse
Randomized controlled trial
Preclinical / animal
Abstract
There is growing interest among the general population in preventive health interventions that can help mitigate age-related decline, reduce the risk of chronic diseases, and promote healthy aging. The use of nutritional supplements has been increasing and is especially high in older adults and healthier individuals. In response to this demand, a growing number of nutritional supplements are being advertised for their "anti-aging" properties, claiming to target molecular and cellular "telomere(definition) attrition, cellular senescence(definition))." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">hallmarks of aging(definition)", such as chronic inflammation, oxidative stress, and cellular senescence. However, the overwhelming majority of these claims stem from preclinical studies in animal models (e.g., C. elegans, mice), and there is extremely limited evidence for beneficial effects, effective doses, or safety profiles of these supplements in humans. Moreover, the lack of strict regulations in the nutritional supplement industry leads to wide differences in the quality and in the actual content of active substances between supplements, which could impact both their efficacy and safety.
The investigators will conduct a clinical trial in healthy volunteers, who will receive supplementation with fisetin (100 mg) or placebo daily for 7 weeks. Participants will be examined at regular intervals during the study period. The investigators will then investigate whether fisetin supplementation is safe and evaluate its effect on measures of chronic inflammation, cellular senescence, aging, and general health.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Anonymous. (2025). Low-dose Fisetin Supplementation for Healthy Aging - a Triple-blind, Randomized, Placebo-controlled Trial. <em>Ove Andersen</em>. https://clinicaltrials.gov/study/NCT07195318
Vancouver
Anonymous. Low-dose Fisetin Supplementation for Healthy Aging - a Triple-blind, Randomized, Placebo-controlled Trial. Ove Andersen. 2025.
BibTeX
@misc{anon2025Lowdos,
title = {Low-dose Fisetin Supplementation for Healthy Aging - a Triple-blind, Randomized, Placebo-controlled Trial},
author = {Anonymous},
journal = {Ove Andersen},
year = {2025},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
SBV Journal of Basic Clinical and Applied Health Science 2025
Open access · CC-BY
The Science of Aging: Therapeutic Approaches to Extend Lifespan and Healthspan
Basic & Clinical Pharmacology & Toxicology 2026
Open access · CC-BY
Low‐Dose Fisetin Supplementation and Its Association With Chronic Inflammation in Middle‐Aged and Older Adults: Study Protocol for a Triple‐Blind, Randomised, Placebo‐Controlled Trial
Gary L. Pierce 2012
Open access · US-GOV
Targeting Inflammation to Treat Cardiovascular Aging in Humans (TIVA Study)
Universidad de Burgos 2024
Open access · US-GOV
Effects of Combined Creatine Monohydrate and β-Hydroxy-β-Methylbutyrate Supplementation on Body Composition, Physical Performance, Quality of Life, Oxidative Stress, and Inflammation in Physically Active Older Individuals Who Underwent a Comprehensive Fitness Program: A Randomized Crossover Clinical Trial
Escola Superior de Saúde - Universidade do Algarve 2026
Open access · US-GOV
Effects of Magnesium Supplementation on Muscle Strength, Muscle Mass, and Physical Performance in Sarcopenic Individuals
Cairo University 2024
Open access · US-GOV